Global Qyr Research

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Enteric Premixed Film Coating Powder – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Enteric Premixed Film Coating Powder market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Acid-labile drugs degrade in gastric fluid, causing reduced efficacy or gastric irritation – but uncoated tablets lack protection. Enteric premixed film coating powder solves this with pH-sensitive polymers (dissolving at pH 5.5–7.0) that protect drugs in the stomach and enable targeted intestinal release. Key drivers include generic enteric formulations, traditional Chinese medicine modernization, and bioavailability improvement.

The global market for Enteric Premixed Film Coating Powder was estimated to be worth US$ 79 million in 2025 and is projected to reach US$ 119 million, growing at a CAGR of 6.1% from 2026 to 2032. In 2024, global production reached approximately 2,830 tons, with an average price of US$ 26,500 per ton.

Enteric premixed film coating powder is a composite powder or pre-blended mixture specifically designed for enteric coating of tablets or granules. It is mainly composed of enteric polymers, excipients, plasticizers, and functional additives. Its primary function is to protect the drug from degradation in the stomach and enable release at specific sites in the intestine, thereby improving drug stability and targeted efficacy. The powder can be directly used in coating or spraying processes and is a commonly used excipient in enteric oral solid dosage forms.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098449/enteric-premixed-film-coating-powder

Market Segmentation & Key Players

The Enteric Premixed Film Coating Powder market is segmented as below:

Leading Suppliers: Colorcon, Kerry, Alsiano, Seppic, Imerys, Tianjing ILE, Yuekang Pharmaceutical Group, Lianyungang Wantai Pharm Excipients Tech, Lianyungang Huanyu Bitumen, Shanghai Inno-polymer Pharmaceutical Technology, Lianyungang Hengyang Pharmaceutical.

Segment by Type: Standard Enteric Type | Controlled-Release Enteric Type | Targeted Enteric Type

Segment by Application: Western Medicine | Traditional Chinese Medicine

Exclusive Industry Insights

Discrete spray-dried powder manufacturing: Enteric premix powders are manufactured via spray drying or dry blending – enteric polymers (methacrylic acid copolymers, HPMCAS, shellac) combined with plasticizers (triethyl citrate, PEG), anti-tack agents (talc, glyceryl monostearate), and pigments. Particle size optimized for aqueous film coating (D90 <50μm).

Technical differentiation – coating types:

• Standard Enteric Type (55% revenue): pH 5.5–6.0 dissolution (upper intestine). For acid-labile drugs, NSAID irritation protection. Largest segment.
• Controlled-Release Enteric Type (30% revenue): Combined enteric + sustained-release. For once-daily formulations, colonic delivery. Fastest-growing (CAGR 7.2%).
• Targeted Enteric Type (15% revenue): pH 6.5–7.0 dissolution (lower intestine/colon). For IBD drugs, peptide delivery. Highest value, specialized applications.

Recent 6-month data (Oct 2025 – Mar 2026):

• Western medicine dominates (72% revenue), including PPIs, NSAIDs, mesalamine.
• Traditional Chinese medicine fastest-growing (CAGR 7.5%), with modernization of herbal tablets.
• Aqueous enteric coating (water-based) now 85% of applications (vs. solvent-based 15%).

User case – Generic PPI manufacturer (India, 5 billion tablets/year): Using standard enteric premix powder (pH 6.0 dissolution) for omeprazole delayed-release tablets achieved bioequivalence to branded product. Coating process: 35–40°C inlet temperature, 15–20% weight gain. Batch-to-batch uniformity improved with pre-blended system.

Application insights: Western Medicine (72%) – PPIs (omeprazole, lansoprazole), NSAIDs (aspirin, ibuprofen), mesalamine (UC), pancreatic enzymes. Traditional Chinese Medicine (28%) – enteric-coated herbal tablets, protecting active compounds from gastric degradation.

Key enteric polymers:

Regional snapshot: Asia-Pacific leads with 52% revenue share (China 38%, India 12%), driven by generic and TCM manufacturing. North America holds 22%, Europe 18%.

Conclusion

The enteric premixed film coating powder market grows steadily, driven by generic enteric formulations, TCM modernization, and targeted delivery demands. Success depends on polymer selection, batch consistency, and aqueous coating compatibility. The projected US$ 119 million market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Medicinal Stevioside – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Medicinal Stevioside market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Diabetes, obesity, and hypertension patients require sugar alternatives with therapeutic benefits – but artificial sweeteners have safety concerns, while natural sugars add calories. Medicinal stevioside solves this as a natural, non-caloric high-intensity sweetener (200–300x sucrose) with demonstrated pharmacological activities including glucose regulation, antihypertensive effects, and anti-inflammatory properties. Key drivers include clean-label trends, metabolic disease prevalence, and functional food demand.

The global market for Medicinal Stevioside was estimated to be worth US$ 95 million in 2025 and is projected to reach US$ 143 million, growing at a CAGR of 6.1% from 2026 to 2032. In 2024, global sales reached approximately 2,140 tons, with an average price of US$ 41,500 per ton.

Medicinal stevioside refers to a group of natural high-intensity sweeteners extracted from the leaves of Stevia rebaudiana Bertoni, primarily composed of diterpene glycosides such as stevioside and rebaudiosides. Beyond its wide application as a non-caloric sweetener in the food industry, medicinal stevioside has demonstrated various pharmacological activities, including glucose regulation, antihypertensive effects, anti-inflammatory, and antioxidant properties. These characteristics suggest its potential therapeutic applications in managing conditions such as diabetes, obesity, and cardiovascular disorders.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098444/medicinal-stevioside

Market Segmentation & Key Players

The Medicinal Stevioside market is segmented as below:

Leading Suppliers: PureCircle, Cargill, Sunrise Nutrachem Group, Crodarom, Merisant, Shandong Huaxian Haosen Biotechnology, Shandong Sugar Baby Biotechnolog, Jilin Aodong Biotechnology, Shandong Jiake Biotechnology, Shandong Haigen Biotechnology, Hunan Erkang Pharmaceutical, Sichuan Bolley Heng Pharmaceutical, BONTAC Biotechnology.

Segment by Type: Purity 95%–98% | Purity 98%–99% | Purity Above 99%

Segment by Application: Pharmaceuticals | Health Supplements | Others

Exclusive Industry Insights

Discrete plant extraction & purification: Medicinal stevioside is manufactured via water extraction of Stevia leaves, followed by multi-step purification (membrane filtration, crystallization, chromatography). Higher purity requires additional processing steps (re-crystallization, HPLC polishing), increasing cost exponentially.

Technical differentiation – purity grades:

• Purity 95%–98% (28% revenue): Technical grade for food/beverage applications. Lower cost, contains mixed glycosides (stevioside + rebaudioside A).
• Purity 98%–99% (48% revenue): Pharmaceutical grade. Reduced off-taste (bitter/metallic notes). Largest segment for supplements and pharma excipients.
• Purity Above 99% (24% revenue): High-purity rebaudioside A or stevioside isolates. For research, clinical studies, and premium formulations. Fastest-growing (CAGR 7.2%).

Recent 6-month data (Oct 2025 – Mar 2026):

• Health supplements largest application (52% revenue), driven by sugar-free and keto products.
• Pharmaceuticals fastest-growing (CAGR 6.8%), with clinical trials for diabetes and hypertension.
• Average price increased 5% due to Stevia leaf supply constraints.

User case – Nutraceutical manufacturer (US, stevia-based supplements): Launching stevioside capsules (250mg, 98% purity) for blood sugar support achieved US$ 15M revenue in first year. Key claim: “supports healthy glucose metabolism.” Repeat purchase rate: 34% (vs. industry avg 22%).

Pharmacological evidence (clinical studies):

Application insights: Health Supplements (52%) – capsules, powders, gummies for blood sugar support, weight management. Pharmaceuticals (35%) – API for anti-diabetic formulations, excipient in oral liquids. Others (13%) – functional foods, medical nutrition, research reagents.

Regulatory status:

• FDA: GRAS for food; no approved therapeutic claims (sold as dietary supplement).
• EMA: Novel food approval; pharmaceutical use under investigation.
• China (NMPA): Listed as food additive and API for traditional medicine.

Regional snapshot: Asia-Pacific leads with 55% revenue share (China 40%, Stevia cultivation + processing). North America holds 25% (supplement demand). South America 12% (Paraguay/Brazil origin). Europe 8%.

Conclusion

The medicinal stevioside market is growing rapidly, driven by metabolic disease prevalence, clean-label demand, and functional health trends. Success depends on purity control, taste improvement (rebaudioside M/A), and clinical evidence generation. The projected US$ 143 million market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Ronidazole – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Ronidazole market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Avian and companion animal protozoal infections (Trichomonas, Histomonas, Giardia) cause significant morbidity and economic loss – but treatment options are limited due to resistance and safety concerns. Ronidazole solves this as a nitroimidazole antimicrobial with potent antiprotozoal activity, used in poultry, pigeons, and companion animals. Key challenges include potential neurotoxicity, strict dosing requirements, and regulatory restrictions in food-producing animals.

The global market for Ronidazole was estimated to be worth US$ 18.99 million in 2025 and is projected to reach US$ 25.08 million, growing at a CAGR of 4.1% from 2026 to 2032. In 2024, global production reached approximately 652,140 units, with an average selling price of US$ 29.1 per unit.

Ronidazole is a nitroimidazole-class antimicrobial and antiprotozoal agent used primarily in veterinary medicine to treat infections caused by anaerobic bacteria and certain protozoa, such as Trichomonas and Histomonas species. It functions by penetrating microbial cells and disrupting DNA synthesis through reduction of its nitro group, leading to cell death. Ronidazole is commonly used in birds (especially poultry and pigeons) and companion animals like dogs and cats for conditions such as histomoniasis (blackhead disease) and giardiasis. Due to its potential toxicity and possible carcinogenicity, it is not approved for use in food-producing animals in many countries and is handled with caution. The compound is typically administered orally and requires strict dosage control to minimize side effects, including neurological toxicity.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098356/ronidazole

Market Segmentation & Key Players

The Ronidazole market is segmented as below:

Leading Suppliers: Glentham Life Sciences, Cayman Chemical, Fengchen Group, Nordic Biosite, Manus Aktteva Biopharma LLP, Simson Pharma Limited, Menadiona.

Segment by Type: Powder | Solution | Tablet

Segment by Application: Poultry Farming | Racing Pigeons and Ornamental Birds | Other

Exclusive Industry Insights

Discrete API synthesis: Ronidazole is manufactured via nitroimidazole chemical synthesis, requiring strict quality control for purity (>98%) and residual solvents. API is then formulated into powder (for mixing with feed/water), solution (oral suspension), or tablets (individual dosing).

Technical differentiation – formulation types:

• Powder (48% revenue): Bulk form for mixing into feed or drinking water. Preferred for poultry farming (mass medication). Largest segment.
• Solution (32% revenue): Ready-to-use oral suspension. For pigeons, ornamental birds, and small companion animals.
• Tablet (20% revenue): Individual dosing for dogs, cats, and birds. Highest value per unit, fastest-growing (CAGR 5.2%).

Recent 6-month data (Oct 2025 – Mar 2026):

• Poultry farming largest application (52% revenue), despite regulatory restrictions in many countries (US, EU banned for food animals).
• Racing pigeons segment fastest-growing (CAGR 5.5%), driven by trichomoniasis prevention in competitive birds.
• Average price increased 6% due to raw material cost inflation.

User case – Racing pigeon breeder (Belgium, 500 birds/year): Using ronidazole solution (50mg/kg) for 5-day course to treat trichomoniasis reduced flock infection rate from 35% to 8% during racing season. Treatment cost: US$ 2.50 per bird; prevented loss of racing performance valued at US$ 500+ per bird.

Application insights: Poultry Farming (52%) – histomoniasis (blackhead disease) in turkeys and chickens, trichomoniasis in breeding flocks. Racing Pigeons & Ornamental Birds (35%) – canker (trichomoniasis), routine prevention during racing season. Other (13%) – companion animals (dogs: giardiasis, cats: Tritrichomonas foetus), exotic birds.

Safety considerations:

• Neurotoxicity risk: At high doses (>/= 100mg/kg) or prolonged use, potential for neurological signs (ataxia, seizures).
• Contraindications: Not for use in food-producing animals in US, EU, Canada, Japan.
• Withdrawal periods: Required in countries where approved (typically 14–21 days for meat, 5–7 days for eggs).

Regional snapshot: Europe leads with 42% revenue share (racing pigeon culture). Asia-Pacific holds 32% (poultry production, less restrictive regulations). North America 18% (restricted use in non-food animals only).

Conclusion

The ronidazole market is niche but stable, driven by racing pigeon health, companion animal giardiasis, and poultry histomoniasis treatment where permitted. Success depends on regulatory compliance, dosing precision, and safety monitoring. The projected US$ 25.1 million market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Long-acting Muscarinic Antagonists (LAMAs) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Long-acting Muscarinic Antagonists (LAMAs) market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: COPD patients require sustained bronchodilation to manage symptoms and reduce exacerbations – but short-acting agents provide only 4–6 hour relief. Long-acting muscarinic antagonists (LAMAs) solve this with once-daily dosing (24-hour duration) by blocking M3 receptors in airway smooth muscle. Key drivers include COPD prevalence, GOLD guideline recommendations, and generic LAMA availability.

The global market for Long-acting Muscarinic Antagonists (LAMAs) was estimated to be worth US$ 2,115 million in 2025 and is projected to reach US$ 2,765 million, growing at a CAGR of 4.0% from 2026 to 2032. In 2024, the average price was approximately US$ 11.67 per unit, with total sales volume of around 175 million units.

Long-acting muscarinic antagonists (LAMAs) are a class of bronchodilators widely used in the management of chronic obstructive pulmonary disease (COPD). They work by blocking M3 muscarinic receptors in the airway smooth muscles, providing sustained bronchodilation. Compared with short-acting agents, LAMAs have a prolonged duration of action, typically lasting for 24 hours, which allows once-daily dosing and improves lung function as well as patients’ quality of life. Representative drugs include tiotropium, usually administered through dry powder inhalers or nebulizers.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098353/long-acting-muscarinic-antagonists–lamas

Market Segmentation & Key Players

The Long-acting Muscarinic Antagonists (LAMAs) market is segmented as below:

Leading Suppliers: Boehringer Ingelheim, Teva Pharmaceutical, Novartis, The Menarini Group, Covis Pharma, Zentiva, Alfasigma, Gebro-Pharma, Kohl Medical, Cipla, GSK, Zhejiang Xianjun Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, Nanchang Helioeast Technology.

Segment by Type: Aclidinium | Glycopyrrolate | Tiotropium | Umeclidinium | Others

Segment by Application: Asthma | COPD | Others

Exclusive Industry Insights

Discrete DPI/nebulizer formulation: LAMAs are formulated as micronized API (<5μm) blended with lactose (DPIs) or aqueous solutions (nebulizers). Receptor binding: LAMAs dissociate slowly from M3 receptors, providing prolonged bronchodilation (24+ hours).

Technical differentiation – LAMA molecules:

Recent 6-month data (Oct 2025 – Mar 2026):

• COPD dominates (92% of revenue), with minimal asthma use (step-up therapy).
• Tiotropium largest segment (58% revenue), generic entry in US (2025) accelerating.
• Triple therapy (LAMA + LABA + ICS) fastest-growing (CAGR 6.5%), preferred for frequent exacerbators.

User case – National health service (UK, 1.2 million COPD patients): Formulary preference for generic tiotropium DPI (post-patent) reduced annual LAMA spend by US$ 65M (38% savings). Adherence rates unchanged (72%), exacerbation rates stable over 18 months.

GOLD 2025 guideline recommendations:

Application insights: COPD (92%) – maintenance therapy for moderate-to-very severe COPD (GOLD Groups B/E). Asthma (6%) – add-on therapy for uncontrolled asthma (off-label, step 5). Others (2%) – off-label uses.

Regional snapshot: North America leads with 48% revenue share (higher branded prices). Europe holds 28% (generic penetration accelerating). Asia-Pacific fastest-growing (CAGR 5.2%), driven by COPD diagnosis improvement and aging populations.

Conclusion

The LAMA market is mature but stable, driven by COPD prevalence, generic tiotropium entry, and triple therapy adoption. Success depends on DPI device usability, patent expiration management, and combination product development. The projected US$ 2.77 billion market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Short-acting Bronchodilators – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Short-acting Bronchodilators market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Asthma and COPD patients require rapid relief during acute attacks – but delayed or inadequate rescue medication can lead to severe exacerbations. Short-acting bronchodilators (SABAs/SAMAs) solve this with fast-acting (3–5 minute onset) bronchodilation via metered-dose inhalers, using APIs like albuterol, levalbuterol, and ipratropium. Key drivers include respiratory disease prevalence, emergency preparedness, and generic availability.

The global market for Short-acting Bronchodilators was estimated to be worth US$ 4,489 million in 2025 and is projected to reach US$ 5,932 million, growing at a CAGR of 4.1% from 2026 to 2032. In 2024, the average global price was about US$ 19.6 per unit, with total sales reaching approximately 220 million units.

Short-acting bronchodilators (SABAs and SAMAs) are critical rescue medications used during acute asthma attacks and COPD exacerbations. Their upstream supply chain involves active pharmaceutical ingredients (APIs) such as albuterol, levalbuterol, and ipratropium, propellants like HFA-134a and HFA-227, and delivery components including aluminum canisters, metering valves, and spray actuators. These key materials are mainly provided by specialized global suppliers such as Linde and Chemours (propellants), as well as Aptar and Lindal (aerosol valves and actuator systems). Due to high technical and regulatory barriers, manufacturers rely on a stable and highly compliant international supply chain. On the downstream side, the primary customers include hospitals, clinics, retail pharmacies, and pharmacy chains, with strong demand in both emergency and home-care scenarios. Leading manufacturers such as GSK, AstraZeneca, Boehringer Ingelheim, and Teva dominate the global market, creating a landscape where branded products and generics coexist.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098340/short-acting-bronchodilators

Market Segmentation & Key Players

The Short-acting Bronchodilators market is segmented as below:

Leading Suppliers: Boehringer Ingelheim, GSK, Teva Pharmaceutical, Prasco Laboratories, Cipla, Lupin Laboratories, Laboratorio Aldo-Union, Polpharma, Jewim Pharmaceutical, Heilongjiang Fulekang Pharmaceutical, Shanghai Pharmaceuticals, Lunan Better Pharmaceutical, China Resources Double Crane Pharmaceutical.

Segment by Type: Albuterol (Salbutamol) | Levalbuterol | Ipratropium | Others

Segment by Application: Asthma | COPD | Others

Exclusive Industry Insights

Discrete pressurized MDI manufacturing: Short-acting bronchodilators are manufactured via pressure-fill process – micronized API suspended in HFA propellant, filled into aluminum canisters with metering valves (50–100μL per actuation). Valve precision critical for dose consistency (±15% per USP).

Technical differentiation – molecule selection:

• Albuterol (68% revenue): Most widely used SABA, 4–6 hour duration, onset 3–5 minutes. Largest segment, multiple generics.
• Levalbuterol (15% revenue): R-isomer of albuterol, fewer cardiac side effects, higher cost. Preferred for sensitive patients.
• Ipratropium (12% revenue): SAMA, slower onset (15 minutes), longer duration (6–8 hours). Often combined with albuterol for COPD.
• Others (5% revenue): Fenoterol, terbutaline (regional markets).

Recent 6-month data (Oct 2025 – Mar 2026):

• Asthma largest application (68% revenue), COPD fastest-growing (CAGR 4.8%).
• Generic albuterol MDIs captured 52% of US market (up from 38% in 2020).
• Propellant transition to low-GWP HFO-1234ze under EU regulation (effective 2026).

User case – Urban health system (US, 1M emergency visits/year): Stocking generic albuterol MDIs in emergency departments and outpatient pharmacies reduced rescue medication cost by 42% (US$ 8.2M annually). Patient outcomes (hospitalization rates, revisit rates) unchanged over 18 months.

Application insights: Asthma (68%) – acute attack relief, exercise-induced bronchospasm prevention. COPD (28%) – acute exacerbation management, adjunct to maintenance therapy. Others (4%) – bronchospasm from other causes.

Key market dynamics:

Regional snapshot: North America leads with 48% revenue share (higher branded prices). Europe holds 24% (strong generic penetration). Asia-Pacific fastest-growing (CAGR 5.8%), driven by asthma/COPD diagnosis improvement.

Conclusion

The short-acting bronchodilator market is mature but growing, driven by generic expansion, respiratory disease prevalence, and emerging market access. Success depends on propellant transition, valve precision, and cost competitiveness. The projected US$ 5.93 billion market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Inhaled Corticosteroids (ICS) Medications – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Inhaled Corticosteroids (ICS) Medications market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Asthma and COPD patients require daily anti-inflammatory therapy to prevent exacerbations – but oral corticosteroids cause systemic side effects. Inhaled corticosteroids (ICS) solve this with targeted airway delivery via dry powder or metered-dose inhalers, minimizing systemic absorption. Key drivers include asthma prevalence, GINA guideline recommendations, and generic ICS availability.

The global market for Inhaled Corticosteroids (ICS) Medications was estimated to be worth US$ 3,512 million in 2025 and is projected to reach US$ 4,474 million, growing at a CAGR of 3.6% from 2026 to 2032. In 2024, the average global price is around US$ 18.7 per unit, with total sales reaching approximately 182 million units.

Inhaled corticosteroids (ICS) are prescription medications that help reduce inflammation in the lungs. They are typically used daily to prevent asthma attacks and are sometimes prescribed for chronic obstructive pulmonary disease (COPD) or other respiratory conditions. ICS medications are commonly delivered via dry powder inhalers, allowing targeted treatment in the airways while minimizing systemic side effects. Examples include Beclomethasone dipropionate (Qvar®), Budesonide (Pulmicort®), Ciclesonide (Alvesco®), Fluticasone (Arnuity®, Flovent®), and Mometasone (Asmanex®).

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098301/inhaled-corticosteroids–ics–medications

Market Segmentation & Key Players

The Inhaled Corticosteroids (ICS) Medications market is segmented as below:

Leading Suppliers: GSK, Chiesi Farmaceutici, Teva Pharmaceutical, Sumitomo Pharma, Cipla, Glenmark Pharmaceuticals, Orion Corporation, Bausch Health, Viatris, Novartis, Covis Pharma, Zentiva, AstraZeneca, Lunan Better Pharmaceutical, Jewim Pharmaceutical, Shanghai Pharmaceuticals, Zhejiang Xianjun Pharmaceutical, Anhui Wellman Pharmaceutical.

Segment by Type: Beclomethasone Dipropionate | Budesonide | Ciclesonide | Fluticasone | Mometasone | Others

Segment by Application: Asthma | COPD | Others

Exclusive Industry Insights

Discrete inhaler manufacturing: ICS medications are formulated as micronized API (<5μm) blended with carrier lactose (for DPIs) or suspended in HFA propellant (for MDIs). Device engineering is critical: consistent dose delivery despite variable patient inhalation flow rates.

Technical differentiation – ICS molecules:

Recent 6-month data (Oct 2025 – Mar 2026):

• Fluticasone largest segment (38% revenue), established market leader.
• Budesonide fastest-growing (CAGR 4.5%) in emerging markets (generic availability).
• Generic ICS share reached 35% in US (up from 22% in 2020).

User case – National health service (UK, 5 million asthma patients): Formulary preference for generic budesonide DPI over branded fluticasone reduced annual ICS spend by US$ 45M (28% savings). Clinical outcomes (exacerbation rates, hospitalizations) unchanged at 24 months.

Application insights: Asthma (78%) – maintenance therapy across all severities (GINA Steps 2-5). COPD (18%) – ICS indicated for eosinophilic phenotype, frequent exacerbators. Others (4%) – allergic rhinitis (nasal sprays), eosinophilic esophagitis.

Guideline-driven prescribing (GINA 2025):

• Step 1: SABA as needed.
• Step 2: Low-dose ICS (plus SABA).
• Step 3: Low-dose ICS/LABA.
• Step 4: Medium-dose ICS/LABA.
• Step 5: High-dose ICS/LABA + add-on therapy.

Regional snapshot: North America leads with 48% revenue share (higher branded drug prices). Europe holds 28% (strong generic penetration). Asia-Pacific fastest-growing (CAGR 4.8%), driven by asthma diagnosis improvement.

Conclusion

The inhaled corticosteroids market is mature but stable, driven by asthma/COPD prevalence and generic expansion. Success depends on device usability, generic competition management, and combination ICS/LABA products. The projected US$ 4.47 billion market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Ciclesonide Inhalation Aerosol – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Ciclesonide Inhalation Aerosol market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Asthma patients require inhaled corticosteroids (ICS) for airway inflammation control – but some ICS agents have systemic side effects or require activation. Ciclesonide inhalation aerosol solves this as a prodrug activated locally in the lungs, offering targeted anti-inflammatory action with minimal systemic exposure. Key drivers include asthma prevalence, preference for once-daily dosing, and favorable safety profile.

The global market for Ciclesonide Inhalation Aerosol was estimated to be worth US$ 171 million in 2025 and is projected to reach US$ 219 million, growing at a CAGR of 3.7% from 2026 to 2032. In 2024, the average global price was approximately US$ 24.6 per unit, with total sales reaching around 6.71 million units.

Ciclesonide Inhalation Aerosol is a prescription medication used for the control and prevention of asthma in adults and children aged 12 years and older. The aerosol delivers fine particles of the active ingredient deep into the airways, effectively reducing airway inflammation. Upstream raw materials include the active pharmaceutical ingredient (API), propellants, and high-purity aluminum aerosol cans. APIs are typically supplied by GMP-certified pharmaceutical ingredient manufacturers, while aluminum cans and excipients are provided by leading global material suppliers to ensure safety, stability, and compliance. Key manufacturers include Covis Pharma, Zentiva, AstraZeneca, Zhejiang Xianjun Pharmaceutical, and Anhui Wellman Pharmaceutical. These companies possess comprehensive pharmaceutical R&D and production capabilities, adhering strictly to Good Manufacturing Practice (GMP) and regulatory standards across multiple regions. Downstream customers consist primarily of hospitals, pharmacies, and healthcare institutions, ultimately serving patients worldwide who require safe, stable, and effective asthma inhalation therapy.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098295/ciclesonide-inhalation-aerosol

Market Segmentation & Key Players

The Ciclesonide Inhalation Aerosol market is segmented as below:

Leading Suppliers: Covis Pharma, Zentiva, AstraZeneca, Zhejiang Xianjun Pharmaceutical, Anhui Wellman Pharmaceutical.

Segment by Type: 80mcg | 100mcg

Segment by Application: Asthma | COPD | Others

Exclusive Industry Insights

Discrete pressurized MDI manufacturing: Ciclesonide MDIs are manufactured via pressure-fill process – micronized ciclesonide API (particle size <5μm) suspended in HFA propellant, filled into aluminum canisters with metering valves. Prodrug activation: ciclesonide converts to active des-ciclesonide via esterases in lung tissue.

Technical differentiation – dosage strengths:

• 80mcg (45% revenue): For mild-to-moderate asthma, pediatric use (12+ years), step-down therapy.
• 100mcg (55% revenue): For moderate-to-severe asthma, patients requiring higher ICS dose. Fastest-growing (CAGR 4.2%).

Recent 6-month data (Oct 2025 – Mar 2026):

• Asthma dominates (88% of revenue), with COPD off-label use growing.
• Generic ciclesonide MDIs entered European market in 2025 (Zentiva), capturing 18% share.
• Once-daily dosing advantage over twice-daily ICS (e.g., beclomethasone, budesonide).

User case – Regional health system (US, 200,000 asthma patients): Formulary addition of generic ciclesonide MDI (100mcg) as preferred once-daily ICS reduced annual drug cost by 22% compared to branded fluticasone (twice-daily). Patient adherence improved from 58% to 71% (once-daily convenience).

Clinical advantages of ciclesonide:

Application insights: Asthma (88%) – maintenance therapy for persistent asthma, step 2–4 per GINA guidelines. COPD (8%) – off-label for eosinophilic phenotype. Others (4%) – allergic rhinitis (nasal spray formulation).

Regional snapshot: North America leads with 58% revenue share (branded Alvesco® market). Europe holds 28% (generic entry in 2025). Asia-Pacific fastest-growing (CAGR 5.2%), driven by asthma diagnosis rates.

Conclusion

The ciclesonide inhalation aerosol market grows modestly, driven by once-daily dosing advantage, favorable safety profile, and generic entry. Success depends on propellant transition planning, generic competition management, and GMP compliance. The projected US$ 219 million market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Metered-Dose Inhalation Aerosols – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Metered-Dose Inhalation Aerosols market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Respiratory diseases (asthma, COPD) require rapid, portable, and precise drug delivery directly to the lungs – but oral medications are too slow, and nebulizers lack portability. Metered-dose inhalation aerosols (MDIs) solve this with pressurized canisters and metering valves delivering consistent aerosolized doses for acute relief or maintenance therapy. Key challenges include propellant transition (HFA to next-generation), patient inhalation technique, and generic competition.

The global market for Metered-Dose Inhalation Aerosols was estimated to be worth US$ 14,530 million in 2025 and is projected to reach US$ 18,520 million, growing at a CAGR of 3.6% from 2026 to 2032. In 2024, the average global price was approximately US$ 18.7 per unit, with total sales volume of around 746 million units.

Metered-Dose Inhalation Aerosols are widely used drug delivery systems for respiratory diseases. They employ a pressurized canister and valve mechanism to deliver the medication in aerosolized form directly into the patient’s airways and lungs. Known for precise dosing, rapid onset of action, and portability, they are extensively utilized for both acute relief and long-term management of conditions such as asthma and chronic obstructive pulmonary disease (COPD).

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098284/metered-dose-inhalation-aerosols

Market Segmentation & Key Players

The Metered-Dose Inhalation Aerosols market is segmented as below:

Leading Suppliers: AstraZeneca, GSK, Chiesi Farmaceutici, Teva Pharmaceutical, Prasco Laboratories, Cipla, Lupin Laboratories, Viatris, Covis Pharma, Boehringer Ingelheim, Napp Pharmaceuticals, Lunan Better Pharmaceutical, Jewim Pharmaceutical, Heilongjiang Fulekang Pharmaceutical, Shanghai Pharmaceuticals.

Segment by Type: Single-ingredient Preparations | Combination Preparations

Segment by Application: Asthma | COPD | Others

Exclusive Industry Insights

Discrete pressurized filling & valve assembly: MDIs are manufactured via cold-fill or pressure-fill processes – drug + propellant (HFA-134a, HFA-227ea) filled into aluminum canisters, sealed with metering valves (25–100μL per actuation). Valve precision is critical: ±10% dose uniformity required.

Technical differentiation – preparation types:

• Single-ingredient Preparations (42% revenue): Albuterol (salbutamol) for rescue, beclomethasone for maintenance, ipratropium for COPD.
• Combination Preparations (58% revenue): ICS/LABA (fluticasone/salmeterol, budesonide/formoterol), SABA/SAMA. Preferred for adherence and convenience. Fastest-growing (CAGR 4.2%).

Recent 6-month data (Oct 2025 – Mar 2026):

• Asthma largest application (52% revenue), COPD fastest-growing (CAGR 4.5%).
• Generic MDIs captured 35% market share in developed markets (up from 25% in 2020).
• Propellant transition to HFO-1234ze (low GWP) initiated by EU regulations (effective 2026).

User case – Regional health system (UK, 500,000 asthma patients): Switching from branded to generic albuterol MDIs reduced annual drug spend by 38% (US$ 18M). Clinical outcomes (hospitalizations, ER visits) unchanged over 24 months. Patient adherence improved due to lower co-pay.

Application insights: Asthma (52%) – rescue (SABA) and maintenance (ICS, ICS/LABA) for all ages. COPD (38%) – maintenance (LABA, LAMA, ICS/LABA) for elderly. Others (10%) – off-label use (bronchiectasis, cystic fibrosis).

Regulatory trends:

• Propellant transition: Montreal Protocol (Kigali Amendment) phasing down HFCs. HFO-1234ze and HFA-152a emerging as low-GWP alternatives.
• Generic approvals: US FDA guidance on MDI bioequivalence (2025) accelerated generic entry.

Regional snapshot: North America leads with 42% revenue share (high branded drug prices). Europe holds 28% (strong generic penetration). Asia-Pacific fastest-growing (CAGR 5.2%), driven by rising asthma/COPD diagnosis.

Conclusion

The metered-dose inhalation aerosols market is mature but growing modestly, driven by generic expansion, combination products, and propellant transition. Success depends on valve precision, bioequivalence for generics, and low-GWP propellant development. The projected US$ 18.5 billion market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp